Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma - Wikidata - thesis-toulmin - TriplyDB

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

http://www.wikidata.org/entity/Q38551337

about

A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update Lenalidomide for the treatment of B-cell lymphoma.Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells.The evolving role of lenalidomide in non-Hodgkin lymphoma.Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.The landscape of new drugs in lymphoma Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.Preparation and Evaluation of Dexamethasone-Loaded Electrospun Nanofiber Sheets as a Sustained Drug Delivery System.Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.Effective management strategies for patients with marginal zone lymphoma.Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.Current trials for frontline therapy of mantle cell lymphoma.Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care?Emerging and investigational therapies for neuroblastoma.Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective.Drug-induced liver injury in Oncology.Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.A clearer light on the role of NK cells in haematological malignancies

P2860

Q26738937-73B7BF6D-3358-470D-9FB2-85E779074AFA Q26751011-5BD797DD-C450-4DD6-9B4E-E761284CAE83 Q28078869-A47E5C17-6EEE-4722-8FF4-73DFE865FDE9 Q30249007-EBF2E3F5-04C9-40F5-90D5-E1460AF3155A Q33595548-C63DD355-76C6-4727-8773-BB4573C2720B Q37076425-41AA100F-2E0C-4AFF-B5B4-0E5737AE1D5F Q38408414-377686A4-4D61-4F2F-B3B4-F728717C6988 Q38612199-F5BBAA25-1238-4265-A3FF-F788446DE235 Q38637599-BA4C3008-3695-4343-9EA6-F4E6560ADBC8 Q38644259-2AFF3B26-A6CD-46A9-B9C4-F9251E962D21 Q38656983-4DF60452-9998-47E1-8474-BED21A958897 Q38668222-1147A873-0914-4357-A1C5-A05E316BA249 Q38744704-36AF42E6-EB31-431B-BB03-8D305BF81A3D Q38800049-1B084482-C1DE-4736-9B91-74CE3B7D3193 Q38805552-DDEF699F-B6C2-4A9E-8E6A-84891D1D3866 Q38897083-11A54D1F-512F-474C-AF07-A9F661ADADAE Q39061630-9F4039B5-297E-40B7-8E43-B6940E5E7F05 Q39136762-F131EC54-FAB8-4C0F-9638-CD42ED8AFD1D Q39175963-586C4D98-2521-4E74-8B16-A89D993BC7E1 Q41286590-4A06B2EA-2878-48AE-AEEE-202D87015DB7 Q41360384-701EFD8D-8B3E-4323-9E9D-F564FF076F78 Q42121830-46D009DB-5B46-486E-A071-CBCB0B4202EC Q46054966-6803BF5E-191D-4EA9-BF1B-9B491DCC19D8 Q47232472-09A1DE48-CF17-4672-BDDC-2A33C333E5C5 Q47278073-5909C248-16FF-4929-9D74-9E7D1094BCD6 Q47387312-61261BDA-2822-42B2-B88A-BABBFDCCB3CB Q48204093-28E922AA-10ED-4C34-AF96-4AE168776266 Q49279565-2B5B83BA-A9D1-42EF-AA85-A2219B58A38C Q49358927-AC339650-2D18-4176-B538-E4F25C934033 Q50048621-931E1DE8-8335-4C44-9A98-D13A80F4DDBB Q50073387-43D4B106-1BDF-45E6-B5F8-0996A57527E0 Q50089372-37599D2B-77FF-43AE-8F66-EED07D912AD7 Q50662188-441D2CE8-FAA3-49C7-AE11-0DD27B2B2F27 Q51606607-7330D72A-A865-4FE6-B04D-D2DB0DC9C5CE Q53730905-4CB445D4-61A0-43C7-83A3-CCD86E84DEEE Q54083100-61BA81A3-D799-432A-8162-468A35530D6F Q59194181-E01CDE44-7CC1-4ECD-9C18-6CC72A606B6B

P2860

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

http://www.wikidata.org/entity/Q38551337

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

@en

type

label

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

@en

prefLabel

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

@en

P1433

Q38551337-DEA5532B-5043-434A-BB3E-15EDE4A21286

P1476

Q38551337-0E5CADB8-21DA-4AB3-BE87-8CDA7EB8EC78

P2093

Q38551337-512506C7-7287-4FE7-A6A4-134B31B870BD

Q38551337-DF64FA7B-ACF9-49BB-B1A4-A341BEF61424

Q38551337-DFD36BFF-F028-47F0-962E-0604F2050423

P2860

Q38551337-00B4B7EF-1171-443B-A0C2-C2F32DD6E453

Q38551337-00E55F37-FCA3-42D1-B0E8-A960EAAB059C

Q38551337-018433D1-3A01-4C6A-9CB4-78FC77720BDD

Q38551337-052A2123-8A32-4F53-8E2C-AC0C56F92AC2

Q38551337-076F8142-DB83-48CD-9CDD-273D37211B08

Q38551337-09567BE0-A22F-4C0C-9CF2-5559BE44C346

Q38551337-097B1A56-08FE-4527-9485-A0D567872F9B

Q38551337-0C0BDCFE-FA82-4F32-9658-2A62C9DDAB71

Q38551337-14DF969A-5E99-429F-97CC-8230F96C06FB

Q38551337-1BD4D606-7B9B-42FD-B341-A1F9530A9E87

P304

Q38551337-E0EA6560-AEE6-4C83-B0FD-B1CDDA2B5B7D

P31

Q38551337-198D0179-31DF-4E34-B9F3-6C7F71B28464

P356

Q38551337-E54DBE85-5F5B-4BB8-830B-3BFAD358BBA5

P407

Q38551337-80933AC3-62BF-4C23-82C1-14FEAEFFFE5C

P433

Q38551337-BFCB4BA6-1572-43EA-936D-99B943798A94

P478

Q38551337-6589D33E-2C10-4F91-8A30-179DD657CBDB

P577

Q38551337-50B49568-B5A9-48F8-897C-2F1D4D334358

P698

Q38551337-E60BEFA4-E3A8-4C66-AD2F-E42E2D596502

P932

Q38551337-CBAE2BF5-895F-4D75-8E47-A612F58A73ED

P356

JCO.2014.59.5363

P1433

Journal of Clinical Oncology

P1476

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

@en

P2093

Franck Morschhauser

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

Nathan Fowler

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Identification of a primary target of thalidomide teratogenicity

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

Oncogenically active MYD88 mutations in human lymphoma

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

P304

2803-2811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.59.5363

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26195701

http://www.w3.org/2001/XMLSchema#string

P932

5320950

http://www.w3.org/2001/XMLSchema#string